Loading publications…
The last 5 uploaded publications
A guiding map for inflammation
Mihai G. Netea, Frances R. Balkwill, Michel Chonchol, Fabio Cominelli, Marc Y. Donath, Evangelos J. Giamarellos‐Bourboulis, Douglas T. Golenbock, Mark S. Gresnigt, Michael T. Heneka, Hal M. Hoffman, Richard S. Hotchkiss, Leo A. B. Joosten, Daniel L. Kastner, Martin Körte, Eicke Latz, Peter Libby, Thomas Mandrup‐Poulsen, Alberto Mantovani, Kingston H. G. Mills, Kristen L. Nowak, Luke O'neill, Peter Pickkers, Tom van der Poll, Paul M. Ridker, Joost Schalkwijk, David A. Schwartz, Britta Siegmund, Clifford J. Steer, Herbert Tilg, Jos W.M. van der Meer, Frank L. van de Veerdonk, Charles A. Dinarello (2017). A guiding map for inflammation. Nature Immunology, 18(8), pp. 826-831, DOI: 10.1038/ni.3790.
Article168 days agoAuthor Correction: A guiding map for inflammation
Mihai G. Netea, Frances R. Balkwill, Michel Chonchol, Fabio Cominelli, Marc Y. Donath, Evangelos J. Giamarellos‐Bourboulis, Douglas T. Golenbock, Mark S. Gresnigt, Michael T. Heneka, Hal M. Hoffman, Richard Hotchkiss, Leo A. B. Joosten, Daniel L. Kastner, Martin Körte, Eicke Latz, Peter Libby, Thomas Mandrup‐Poulsen, Alberto Mantovani, Kingston H. G. Mills, Kristen L. Nowak, Luke O'neill, Peter Pickkers, Tom van der Poll, Paul M. Ridker, Joost Schalkwijk, David A. Schwartz, Britta Siegmund, Clifford J. Steer, Herbert Tilg, Jos W.M. van der Meer, Frank L. van de Veerdonk, Charles A. Dinarello (2020). Author Correction: A guiding map for inflammation. Nature Immunology, 22(2), pp. 254-254, DOI: 10.1038/s41590-020-00846-5.
Article168 days agoA first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
Shahneen Sandhu, K. Papadopoulos, Peter C.C. Fong, Amita Patnaik, Christina Messiou, David Olmos, George Wang, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Shobha Seetharam, Johann S. de Bono, Anthony W. Tolcher (2013). A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors. , 71(4), DOI: https://doi.org/10.1007/s00280-013-2099-8.
Article62 days agoPre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.
Martin Förster, Amita Patnaik, Shahneen Sandhu, K. Papadopoulos, Brenda Tromp, Christina Messiou, Frances R. Balkwill, Birge Berns, Johann S. de Bono, A. W. Tolcher (2010). Pre-final analysis of first-in-human, first-in-class, phase I clinical trial of CNTO 888, a human monoclonal antibody to the CC-chemokine ligand 2 (CCL2) in patients (pts) with advanced solid tumors.. , 28(15_suppl), DOI: https://doi.org/10.1200/jco.2010.28.15_suppl.2548.
Article62 days agoAbstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors
Shahneen Sandhu, Peter C.C. Fong, Amita Patnaik, K. Papadopoulos, Christina Messiou, Susan Hoare, David Olmos, Brenda Tromp, Thomas A. Puchalski, Frances R. Balkwill, Birge Berns, Johann S. de Bono, Anthony W. Tolcher (2009). Abstract A102: First-in-man, first-in-class, pharmacokinetic and pharmacodynamic phase I clinical trial of a human monoclonal antibody CNTO888 to CC-chemokine ligand 2 (CCL2) / monocyte chemoattractant protein (MCP-1) in patients with advanced solid tumors. , 8(12_Supplement), DOI: https://doi.org/10.1158/1535-7163.targ-09-a102.
Article62 days ago